BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32524539)

  • 1. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma.
    Vitellius C; Griveaux O; Morvant B; Pedrono E; Venara A; Ingster O; Baize N; Dincuff E; Rousselet MC; Guardiola P; Caroli-Bosc FX
    Mol Diagn Ther; 2020 Aug; 24(4):443-449. PubMed ID: 32524539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 8. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
    Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
    J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Sequencing of Pancreatic Adenocarcinomas from Patients with Metachronous Pulmonary Metastases.
    Hlavac V; Mohelnikova-Duchonova B; Lovecek M; Ehrmann J; Brynychova V; Kolarova K; Soucek P
    Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33255265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
    Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9.
    Ono M; Ono Y; Nakamura T; Tsuchikawa T; Kuraya T; Kuwabara S; Nakanishi Y; Asano T; Matsui A; Tanaka K; Ebihara Y; Kurashima Y; Noji T; Murakami S; Shichinohe T; Mitsuhashi T; Omori Y; Furukawa T; Taniue K; Suzuki M; Sugitani A; Karasaki H; Mizukami Y; Hirano S
    Ann Surg Oncol; 2022 Aug; 29(8):5007-5019. PubMed ID: 35399143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
    Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
    Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer.
    Stuart CM; Kirsch MJ; Zhuang Y; Meguid CL; Sugawara T; Colborn KL; Messersmith W; Lieu C; Gleisner AL; Del Chiaro M; Schulick RD; Meguid RA
    Surgery; 2023 Sep; 174(3):654-659. PubMed ID: 37391327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.